Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
oh my oh my...
so for those "WORD" experts ...
who still don't comprehend the original 9 Dr post
here it is again - in all it's glory - and BS debunking Karma
served-up to you - just like Room Service - eh Wordie...?
correctamundo - gotts to churn the float a number of times
shy of a miracle hedgie coming in and taking a sizable position
ASCM’s bot will continue to rule on low volume days
news of a cash flow positive equity target with audited financials and millions of $$$ on the books
will change ASCM’s tune in a NY second
BAF MONI
you LIE bigley
never said you said ….!
only that you thought it
for a poster that has adopted the word “word” for his/her alias
you sure do need correcting offen
SMH - nuff said
MOO desperate
word on the street is …
TOMDF is financially destitute and patently broke
with ongoing -$5-Mil qtrly. burn contributing to a massive overall cumulative & growing loss
expect more OS increases and resultant dilution
crowdfunding is not the way to financial solvency on an unproven OTC supplement
nor may it be anywhere near sufficient to raise the requisite $5-Mul for further Tollo testing
heading to $0.0002 pps
SMH - sad but true
MOO pathetic
past mention of MONI’s target equity having audited financials
followed by substantive positive cash flow and involves potential subsidaries
it may counter one’s suspect claim of RS for monetary need & resulting eviceration of SH interest
not all RS’s are destitute funding to undue the ill effects of toxic death spiral shams - lolzzz
BAF MONI
even you wondered where she went
a token visit - not that it matters much
going after cancer - really Doc....?
TOMDF is broke and doesn't have enough funding to conduct test trials
and the good Doc Arad is going after cancer - really...?
keep drinkin Pal - at $0.0003 pps you might want to add a little Cherry flavor to that toxic mix:
SMH - nuff said
MOO putz
it’s a comparison MaRiA and a point of view
I could care less whether you dont care about a comparison made against TOMDaFk or not, which by the way the CEO takes down $760k annually while fleecing his SH’s with toxic death spiral convertibles - something quite removed from MONI’s financial framing
point is - Frank came in a radically reduced the share count and funded the vast majority of MONI out of pocket - a rare action in todays OTC world - even “Louise” would comprehend that - so get a grim already - ghesh - so dramatic
BAF MONI
oh paleeese MaRiA
your crazy sir - that is infinitesimal - and if I'm not mistaken, some of that had to do with the former WOGI owner and a TA screw up of +/- 30-Mil. accounted for shares unbeknownst to Frank
otherwise Frank has carried MONI from inception and funded it out of pocket
go pound salt - you have no idea what toxic death spiral conversion dilution is...!
go look at TOMDaFk dilution, then come back here spewing your vitriol and venom
BAF MONI...!
there has been no dilution from Frank the whole time he has been involved in MONI
but you already knew that - no whoa’s necessary
it has not been until recent that there has been a small increase in the equity distribution count
nothing new - nothing alarming …!
FO has funded MONI the whole way thru without dilution
SMH - no drama required
BAF MONI
unfortunately, MONI’s share price ain’t going to really move much until…
- Frank stops issuing shares to consultants
- Frank curtails his own equity distribution of shares (dilution)
- Frank announces closure of the RM with final terms reached
other than that, the pps will languish lower until he takes action…!
nothing else really matters until then
BAF MONI
more obfuscation & spin folks
from the TOMDF Back Office Promo Boyzzzz
PR's are a perfect time to crank up the printing press and Dilute Dilute Dilute...!
oh brother - IMHO just more obfuscation and word salad folks from the infamous Reddit alias changing JFB
just another lame and 'kick the can down the road' Tweet by Gerald from Sept 23, 2022....
umh - 14 months ago no less - LMAO
I guess Redskee didn't think anyone would cop-on to this Slim Shady and 3 Card Monty quick post hustle...!
just more proof of obfuscation, spin, and outright deception with TOMDF Back Office Promo Boyzzzz and 9 horsee race...
printing $0.0003 w/ +3-Bil OS already printed and 7-Bil. more to come -
SMH - this just gets more hysterical every weekly gang
crowdfunding ain't going to cut shite
peeps loose everything on crowdfunding shams bigley:
MOO putz
typical - the question that Getald - twice failed serial diluting non-SEC Reporting Stanford University “Financial Engineering” CEO hack fails to answer is….
What’s the profit margin ….?
TOMDF always typical always obfuscation
no surprise there ….!
MOO obvious
see just more obfuscation Les...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173253317
these TOMDF Back Office Promo Boyzzzz really don't want to answer your questions ...!
they have 'other' motives - wink wink...!
MOO ditzy
sure you did...!
right you are Les…
“and the truth shall set you free”
yes, even for Mr Redspeed and JoeyForkitbolo…!
most peeps these daze simply can’t handle the truth
or will try to obfuscate it, deny it, or spin it into something different
so many aliases, so many motives - it’s becomes all too easy for one to be confused…!
isn’t that right Wordman - or is it Redspeed…?
ha, printing $0.0003 w/ +3-Bil OS & climbing quickly is all the “truth” anyone needs to know
no, no pictures needed for this one
TOMDF’s truth is glaring enough
reality - what a concept…!
MOO unreal
gotta love it...
unfortunately if you have to ask….
then you need more help than I have to offer
sad but true
BAF MONI
what hooie…!
this is better than reading a bad Harlequin Romance novel…
MONI will surprise
SMH - nuff said…!
AJMHO
what shite…!
hate? wowza Wordie
get a grip brah - you’re becoming delusional
I get it though - printing $0.0003 will do that
chillaxa …
are you kidding me
Todos has nothing to offer - don't cha know Redsee - just lookie here:
TOMDF's Stable of 50 Horsies & Every Good Reason to Run From the TOMDF Coral:
01. playing/sponsoring 'flag-football' is good for shareholders
02. issuing free shares to Wall St. 'has-beens' will attract new investors
03. hiring an 'x-body builder' for PR is a wise decision
04. hiring a 'kiddie influencer' is a sound decision
05. hiring a TaiBo instructor for Todos promotions is going to reverse serial dilution
06. holding photo op's w/ Michael Irvin and NYSE backdrop is good marketing strategy
07. selling 'gummy bears' is the way of the future
08. selling 'no-name' high priced vending machine products is smart
09. has 10-Bil. AS avalanche over-hang on the heads of shareholders is smart
10. has 3-Bil. In OS folks, yes that 3-BILLION shares issued folks
11. now OTC Compliant and is non-reporting
12. thinks serial diluting the shit out of existing shareholders monthly is "financial engineering"
13. issues fake "Word Salad" tweets & PR's repeatedly and non-stop
14. $5-Mil. qtrly. losses on the books and growing
15. desperate crowdfunding offering which won’t raise diddly
16. promotes Israel & Greece EAU’s - but never gets it done
17. keep saying major news is coming - but somehow it never does
18. only issue conference news like JPM and the pps goes down – mostly on ‘sell the news’ dilution
19. CEO spends all day on Twitter arguing with MD & PhD’s thinking it’s a smart idea
20. investing in failed Para Moto CV-19 mobile test labs amounting to dire financial losses
21. $50-Mil. vending machine business unable to launch due to "cash flow" shortages per CEO
22. crowdfunding financial assistance way behind with missed launch schedules & dates
23. fake spokesperson RS answering MB posts on behalf of company with ulterior motives
24. GC spends all day on Twitter - shareholders quote him thinking GC’s statements are the truth
25. the deal to sell 3-CL expired Dec 31st w/Dr. Orad - still nothing except CEO on Twitter rant
26. Provista employees snot paid, complaining on public forums – GC didn’t want to meet w/them
27. Monkey Pox test kits only made it to a public GA grammar school – where’s distribution of kits
28. Pres. Biden ends COVID Pandemic on 01/30/23 – Tollovid sales will drop bigley
29. CEO trying desperately to jump on LH-COVID wagon, but that’s a risk, as in all eggs in 1 basket
30. Lympro…? oh yeah - waiting for the ‘German’ polices list of approval before releasing the results
31. Videssa commercialized in 2023? yeah right – no Tollovid LH COVID data is very disturbing
32. just how many Tollovid bottles have been sold - when - what’s the total ROI – seems sketchy
33. just what’s happening with the purchase of the ultra-expensive Texas facility
34. Tollovid sales that have never materialized
35. monkeypox testing that’s brought in next to zero revenue
36. crowdfunding campaign that turned out to be a complete dud
37. 3CL Todos in China - GC said they’re sending samples - where exactly did they send them?
38. has 1:500 SH approved RS in filings just waiting for the right time to ‘drop the bomb’
39. Uplist in 2nd half of 2021 | we’re focused on creating SH value for our SH’s – my arse
40. TOMDF plans to launch Vedessa clinical study in 2022 in order to drive sales by 2023 my arse
41. CEO says NasDaq Uplisting 1st half of 2022, NCL Pharma acquisition of track – my arse
42. “As a result, we have our hospitalized COVID Program on pause" - say bye-bye to any EAU folks
43. Tollovir is dead - website was down for a week - dilution is through the roof.
44. Crowdfunding non-existent, botanical CBD Gummy Bears have gone nowhere
45. Employees being laid off left and right, let alone actually being paid
46. TOMDF is now PINK Delinquent non-reporting
47. dilution toxic death spiral financing will keep all TOMDF SH’s broke, you’ll NEVER get your $ out
48. GC unable to close a deal with Arad and NCL for IP rights to all things Tollo
49. Todos will now own 100% of 3CL Pharma but only has distribution rights of Tollo products in NA
50. all that TOMDF SH’s now have is distribution rights
MOO broke
I think you need to catch up on your PR reading Redspudder
the ratchet spinning grease mechanic's tricks won't work on these beauties
and to think TOMDF is printing $0.0003 folks - now how can that be when we have years of worthless PR's...?
TOMDF Sham Exposed in PR Chronological Order Timeline
Todos Medical Provides Corporate Update: Retooling to Focus on Long COVID Epidemic
Sep 26, 2023 11:01am EDT
Todos Announces Notice of Allowance From USPTO for Patent Application Covering Use of Compositions In Tollovid™ and Tollovir™ Ingredients
Aug 30, 2023 8:19am EDT
Todos Medical Enters Into Letter of Intent for Provista Diagnostics to License PCR-based Sepsis Diagnostic Test AcuSept LDT Rights From Acumen Diagnostics
Mar. 28, 2023
Todos Medical Begins Trading on the OTC Pink Marketplace
Mar. 27, 2023
Todos Medical Supports Long COVID Awareness Day
Mar. 15, 2023
Todos Medical Enters Into Moratorium on Conversions Agreement With Convertible Note Holders
Mar. 13, 2023
Todos Medical Initiates Validation Plan for PCR-based Avian Influenza A (H5N1, Bird Flu) Test at CLIA/CAP Testing Lab Provista Diagnostics
Feb. 14, 2023
Todos Medical to Present at the RHK 2022 Disruptive Growth Conference
Dec. 06, 2022
Todos Medical’s 3CL Pharma Awarded Oral and Poster Presentations at World Antiviral Congress 2022
Nov. 29, 2022
Todos Medical to Attend World Antiviral Congress
Nov. 22, 2022
Todos Medical Enters Into Exclusive Worldwide Automated Retail Supply Agreement With Smart Automated Retail Network
Nov. 16, 2022
Todos Medical Terminates Tollovid™ Products License & Distribution Agreement with T-Cell Protect Hellas S.A.
Nov. 10, 2022
Todos Medical CLIA/CAP Lab Provista Submits Emergency Use Authorization Application for MonkeyPox PCR Test to US FDA
Oct. 14, 2022
Todos Medical Announces Successful Pilot Launch of Suite of PCR Testing Services by CLIA/CAP Lab Provista Diagnostics
Oct. 06, 2022
Todos Medical Receives Two Notices of Allowance from USPTO for AI-Based TBIA Pan-Cancer Blood Diagnostics Platform
Sep. 30, 2022
Todos Medical Announces USPTO Trademark Notice of Allowance for 3CL Protease Biomarker Diagnostics TolloTest™
Sep. 27, 2022
Todos Medical Enters Into $50M Contract to Supply Tollovid™ and CBD Products to Retail Distributor Company Nerd Hemp
Sep. 22, 2022
Todos Medical Announces NFL Hall of Famer Michael Irvin as Tollovid™ Sports Ambassador for #TolloUp Campaign
Sep. 16, 2022
Todos Medical Announces Preprint of Long COVID Case Study Participant with Confirmed Microclot and Hyperactivated Platelets who Benefitted from Tollovid
Sep. 15, 2022
Todos Medical & The Alchemist’s Kitchen to Host “Long COVID: An Integrated Approach” Event Benefitting Survivor Corps
Sep. 13, 2022
Todos Medical’s 3CL Protease Inhibitor Supplement Tollovid™ Featured in Wellness Magazine
Sep. 13, 2022
Todos Medical Partner NLC Pharma Assigns IP for Tollovir™, Tollovid™, and TolloTest™ into JV 3CL Pharma
Sep. 12, 2022
Todos Medical CEO Discusses Long COVID Economic Impact with Moneta Advisory Managing Partner Marc LoPresti
Sep. 09, 2022
Todos Medical Announce Kingcarlx as Brand Ambassador for the Tollovid #TolloUp Lifestyle Campaign
Sep. 02, 2022
Todos Medical Establishes Botanical Supplement Manufacturing Capabilities to Support Tollovid Global Expansion and Initiates CBD-A Production
Aug. 31, 2022
Todos Medical Expands COVID Onsite School Sample Collection to Include MonkeyPox Testing
Aug. 29, 2022
Todos Medical Announces Saliva-Only MonkeyPox Testing at CLIA/CAP Clinical Lab Provista Diagnostics
Aug. 26, 2022
Todos Medical Enrolls Female Long COVID Patient Unable to Secure Testing While Symptomatic for MonkeyPox into Provista Diagnostics Case Study Series
Aug. 25, 2022
Todos Medical Initiates MonkeyPox Diagnostic Case Studies After Being Approached by 4 Patients, Including 3 Women
Aug. 23, 2022
Todos Medical Announces Commercialization of Lesion and Saliva-Based MonkeyPox PCR Testing
Aug. 22, 2022
Todos Medical Announces Preprint of Data from First 100 Participants in IRB-waived Market Research Study of Supplementation with Tollovid in Long COVID
Aug. 19, 2022
Todos Medical Reports Pre-Print of Publication Detailing Tollovid Supplementation Following COVID-19 mRNA Vaccination in Long COVID
Aug. 15, 2022
Todos Medical Completes Trial Design for Tollovid™ Long COVID Clinical Study in Adults
Aug. 11, 2022
Todos Medical Announces PCR Validation of Wound and Respiratory Pathogen Panels at CLIA/CAP Lab Provista Diagnostics
Aug. 10, 2022
Todos Medical Announces First Two Contracts for PCR-based MonkeyPox Testing at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics
Aug. 08, 2022
Todos Medical Announces First Long COVID Clinic Laboratory Services Agreement for Long COVID Panel Biomarker Partnership with Amerimmune Diagnostics
Aug. 05, 2022
Todos Medical Initiates Validation Plan for PCR-based MonkeyPox Test at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics
Aug. 03, 2022
Todos Medical Announces Preprint of Acute COVID-19 Paxlovid Rebound Rescued by Tollovid
Aug. 01, 2022
Todos Medical Partners with Amerimmune Diagnostics on Long COVID Biomarker Panel
Jul. 28, 2022
Todos Medical Announces Preprint of Chronic Long COVID Case Study #8 of Paxlovid® Treatment Followed by Tollovid™ Dietary Supplementation
Jul. 22, 2022
Todos Medical Reports Case Study #7 in Acute and Long COVID
Jul. 12, 2022
Todos Medical Announces Positive Biomarker Data from Phase 2 Trial of Tollovir in Hospitalized COVID-19 Patients
Jun. 30, 2022
Todos Medical Releases Preliminary Data From IRB-Waived Tollovid® Market Research Study in Acute and Long COVID
Jun. 23, 2022
Todos Medical Retains Moneta Advisory Partners as Strategic Advisors for National Exchange Listing and 3CL Pharma Spinoff
Jun. 21, 2022
Todos Medical Completes Validation of 27 Pathogen UTI PCR Panel at Its CLIA/CAP Laboratory Provista Diagnostics
Jun. 13, 2022
Todos Medical Reports Day 45 Update for Case Study #6
Jun. 10, 2022
Todos Medical Reports Day 28 Update for Case Study #5 with Erectile Dysfunction
Jun. 07, 2022
Todos Medical Announces Enrollment Complete for Confirmatory Cohort of LymPro Alzheimer’s Blood Test Clinical Validation Trial vs. Amyloid PET
Jun. 03, 2022
Todos Medical Reports Day 26 Update For Case Study #4
Jun. 01, 2022
Todos Medical to Present Final Data from the Tollovir Phase 2 Clinical Trial in Hospitalized COVID-19 Patients at the Personalized Medicine World Conference
May 27, 2022
Todos Medical Reports Day 14 Update from Ongoing 30-Day Case Study of Paxlovid Rebound Patient
May 06, 2022
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength Including 5 Day Dosing, 30 Day Dosing and 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim
May 02, 2022
Todos Medical Initiates IRB-Waived Tollovid Market Research Study and Announces 50% Price Reduction Until May 30th, 2022
Apr. 27, 2022
Todos Medical Appoints Philippe Goix as Chief Commercial Officer for Provista Diagnostics
Apr. 21, 2022
Todos Medical Reports 2nd Long COVID Case Study and Launches Website for Physicians and Pediatricians to Indicate Interest in Participating in Tollovid Long COVID Clinical Study
Apr. 20, 2022
Todos Medical Targets Athlete Support with Informed Sport Certification for Tollovid by LGC Group
Apr. 19, 2022
Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid® US FDA Certificate of Free Sale with Daily and Acute Dosing on the Label
Apr. 06, 2022
Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants
Apr. 04, 2022
Todos Medical Reports Case Study of Patient with Long COVID
Mar. 31, 2022
Billy Blanks® Endorses Todos Medical’s Line of Tollovid® Products
Mar. 28, 2022
Todos Medical Completes Acquisition of Key Assets and Intellectual Property from NLC Pharma
Mar. 16, 2022
Todos Medical Appoints Greg Meiselbach as Vice President of Government Affairs
Mar. 08, 2022
Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir™ in the Treatment of Hospitalized COVID-19 Patients
Jan. 27, 2022
Todos Medical Announces Data Lock in Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients
Jan. 24, 2022
Pepperdine University Hosts the 22nd Annual Celebrity Flag Football Challenge®, Presented by Todos Medical’s Tollovid®
Jan. 19, 2022
Todos Medical Releases Videos of Recent CEO Interviews with Fox Business, NewsMax and Black News Channel on COVID Testing & Treatment Strategies
Jan. 18, 2022
Todos Medical to Announce Topline Results from Tollovir™ Phase 2 Clinical Trial from the Treatment of Hospitalized COVID-19 Patients on January 27th, 2022
Jan. 12, 2022
Todos Medical CEO to Appear on Fox Business to Talk COVID Testing & Tollovir on Tuesday, January 11, 2022 and is Presenting at Biotech Showcase 2022
Jan. 10, 2022
Todos Medical Records Record Weekly COVID PCR Testing Volumes at Provista
Dec. 27, 2021
Todos Medical CEO to Appear on Yahoo Finance Live! at 12:10PM EST with Akiko Fujita to Talk Pfizer’s Paxlovid Approval, Tollovir™ Phase 2 & COVID Testing
Dec. 23, 2021
Todos Medical Announces New cPass Neutralizing Antibody Testing Reference Lab Agreement for CLIA/CAP Lab Provista with Physician Group in 40 States
Dec. 22, 2021
Todos Medical Appoints Valentino Smith, MBA as Vice President of Marketing
Dec. 20, 2021
Todos Medical Announces “Test & Tollovid®” Holiday Package for Atlanta Area at Provista Diagnostics
Dec. 17, 2021
Todos Medical to Host Key Opinion Leader Webinar Entitled Tollovir™: a Potential Treatment for Covid-19
Dec. 16, 2021
Todos Medical Enters 90-Day Extension of Agreement with Convertible Note Holders on Moratorium on Conversions of Convertible Notes
Dec. 13, 2021
Todos Medical Interview and Presentation on Benzinga's All Access Conference Live December 14th at 10:20 AM EST
Dec. 10, 2021
Todos Medical Announces 2 New COVID-19 PCR Testing Reference Lab Agreements for CLIA/CAP Lab Provista Diagnostics
Dec. 07, 2021
CEOs Presenting at the Emerging Growth Conference on December 8; Register Now
Dec. 07, 2021
Todos Medical to Present at Upcoming Emerging Growth Conference
Dec. 06, 2021
Todos Medical Announces All 31 Patients Enrolled to Date in Tollovir® Phase 2 Clinical Trial in Hospitalized COVID-19 Patients Have Completed Study Participation
Dec. 02, 2021
Todos Medical Confirms SARS-CoV-2 PCR Test Kits Used at CLIA/CAP Lab Provista Diagnostics Detect Omicron Variant
Nov. 30, 2021
Todos Medical Enters into Binding Agreement to Acquire All 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma
Nov. 29, 2021
Todos Medical Receives Purchase Order for 50,000 Bottles of Tollovid Daily from Its European Distribution Partner T-Cell Protect Hellas S.A for Initial Market Launch in Greece
Nov. 22, 2021
Todos Medical Announces Completion of Enrollment for COVID-19 Oral Antiviral 3CLPro (Mpro) Inhibitor Tollovir Phase 2 Clinical Trial Interim Analysis in Severe and Critical Hospitalized Patients
Nov. 19, 2021
Todos Medical Announces Tollovid® Products Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. Covering 30 Countries in Europe
Nov. 18, 2021
Todos Medical Announces Addition of Semi-Quantitative Titer Claims to the Emergency Use Authorization for the cPass Neutralizing Antibody Test
Nov. 17, 2021
Todos Medical’s Provista Laboratory to Boost Top Line Through New Atlanta-based Reference Lab Agreement for COVID PCR, cPass Neutralizing Antibody & Respiratory Pathogen Panel Tests
Nov. 16, 2021
Todos Medical Reports Third Quarter 2021 Business and Financial Results
Nov. 15, 2021
Todos Medical Sees Significant Ramp Up in COVID PCR Testing Volume at Its Provista CLIA/CAP Lab with New Automation in Place
Nov. 02, 2021
Todos Medical Announces 2nd Clinical Trial Site for Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients
Nov. 01, 2021
Todos Medical Announces Publication in Nature Neuroscience That Describes the Main Protease (3CL Protease) Causes Microvascular Brain Pathology
Oct. 25, 2021
Todos Medical Announces Publication in Journal of Clinical Virology Highlighting Clinical Utility of cPass Semi-Quantitative Neutralizing Antibody Test in SARS-CoV-2 Risk Assessment Post-Vaccination or Recovery from Infection
Oct. 21, 2021
Todos Medical to Conduct Webinar Highlighting the cPass SARS-COV-2 Neutralizing Antibody Test for AMDA, The Society for Post-Acute and Long-Term Care Medicine, on October 22, 2021 at 12:00 PM EDT
Oct. 14, 2021
Todos Medical Announces Positive Data in Hospitalized and Outpatient Setting for TolloTest™, a Novel SARS-CoV-2 3CL Protease Biomarker Assay
Oct. 06, 2021
Todos Medical Provides Update on COVID-19 Oral Antiviral 3CL Protease (Main Protease) Inhibitor Tollovir Clinical Development Program in Light of Molnupiravir Clinical Trial Data from Merck
Oct. 04, 2021
Todos Medical Announces Positive Observational Trial Results for Oral Antiviral 3CL Protease (MPro) Inhibitor Tollovir®
Sep. 30, 2021
Todos Medical Receives Approval by Amazon to Sell Immune Supplements Tollovid® & Tollovid Daily™
Sep. 27, 2021
Todos Medical Reports Second Quarter 2021 Financial Results
Fri, Sep. 24, 2021
UPDATE: Todos Medical Announces 90-Day Moratorium on Conversions of Convertible Notes and Lockup of Common Stock Sales with Convertible Note Holders
Sep. 24, 2021
Todos Medical Launches Tollovid Daily™ via Subscription at MyTollovid.com
Sep. 23, 2021
Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Oral Antiviral Drug Candidate Tollovir™
Sep. 20, 2021
Todos Medical Now Accepting Cryptocurrency for the Purchase of Tollovid® and Tollovid Daily™ Through Coinbase Commerce
Sep. 17, 2021
Todos Medical Announces 90-Day Moratorium on Conversions of Convertible Notes and Lockup of Common Stock Sales with Convertible Note Holders
Sep. 15, 2021
Todos Medical’s CLIA/CAP Lab Provista Completes Validation of Combination COVID, Influenza A & B, RSV & hMPV Respiratory Panel Test
Sep. 01, 2021
Todos Medical’s CLIA/CAP Lab Provista Completes Validation of High-Capacity SARS-CoV-2 Variant Testing Service Capable of Identifying Known Variants
Aug. 26, 2021
Todos Medical’s CLIA/CAP Lab Provista Enters Into Reference Lab Agreement with Meadowlands Diagnostics to Provide cPass Neutralizing Antibody Blood Testing for Quantifying and Monitoring Key COVID-19 Immunity Biomarkers
Aug. 24, 20211
Todos Medical Completes Validation of cPass Neutralizing Antibody Blood Test at Provista Diagnostics to Quantify and Monitor Key Biomarkers of COVID-19 Immunity
Aug. 23, 2021
Todos Medical CEO to Appear on Fox Business Network Varney & Company Today at 11:40am to Discuss the Company’s Launch of cPass Neutralizing Antibody Testing for Monitoring COVID-19 Immunity
Aug. 23, 2021
Update: Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Dietary Supplement Tollovid™
Aug. 05, 2021
Todos Medical Receipt Notice of Allowance from USPTO for 3CL Protease Inhibitor Dietary Supplement Tollovid™
Aug. 05, 2021
Todos Medical Makes Final Payment to Close Provista Diagnostics Acquisition
Aug. 02, 2021
Todos Medical Retains CRO for COVID-19 Outpatient and Inpatient Phase 2/3 Clinical Trials for Oral Antiviral 3CL Protease Inhibitor Tollovir
Jul. 28, 2021
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid Daily™ Including 3CL Protease Inhibitor Claim
Jul. 22, 2021
Todos Medical to Launch EUA Authorized cPass SARS-CoV-2 Neutralizing Antibody Kit Through Agreement with Fosun Pharma
Jul. 19, 2021
Todos Medical Appoints Ilanit Halperin, CPA as Corporate Controller
Jul. 07, 2021
Todos Medical Receives FDA Certificate of Free Sale for New 5-Day Tollovid Dosing Regimen
May 04, 2021
Todos Medical Launches Phase 2 Clinical Trial of Its Antiviral 3CL Protease Inhibitor NLC-V-01 (Tollovir) in Hospitalized COVID-19 Patients
Apr. 19, 2021
Todos Medical Receives Notice of Allowance from European Patent Office for Patent Application Covering Diagnosis of Cancer Using Proprietary Artificial Intelligence TBIA Immune Profiling Platform
Apr. 08, 2021
Todos Medical Completes Automation Equipment Installation and Training for Meadowlands Diagnostics
Apr. 01, 2021
Todos Medical Enters Into Distribution Partnership with Osang Healthcare for the GeneFinder Plus™ COVID-19 Plus RealAMP Kit in the United States
Mar. 30, 2021
Todos Medical Completes Automation Equipment Installation and Training for a Laboratory Client in Brooklyn, NY
Mar. 29, 2021
Todos Medical Enters Into Automation and Reagent Supply Agreement with MAJL Diagnostics
Mar. 23, 2021
Todos Medical Announces $7.2M in Sales for February 2021, a 38% Month Over Month Increase From Sales of $5.2M in January 2021
Mar. 12, 2021
Todos Medical Applauds Senate and House Passage of the American Recovery Act
Mar. 11, 2021
Todos Medical Announces Strategic Investment by Yozma Group Korea
Jan. 25, 2021
Todos Medical Announces $4.8 Million in Sales for December 2020, a 50% Month Over Month Increase in Sales from November 2020
Jan. 11, 2021
Todos Medical Announces Agreement to Supply Natural Wellness Clinics with COVID-19 Testing Products to Support Initiatives in the Commonwealth of Kentucky
Dec. 23, 2020
Aditxt Signs Distribution Agreement with Todos Medical Ltd. For AditxtScore™ for COVID-19 Immune Monitoring Service
Dec. 14, 2020
Todos Medical Announces Commercial Launch of Proprietary 3CL Protease Inhibitor Dietary Supplement Tollovid™ at The Alchemist’s Kitchen
Dec. 07, 2020
Todos Medical Announces $3.2 Million in Sales for November 2020, a 269% Increase Sequential Month over Month Sales Growth from October 2020
Dec. 02, 2020
Todos Medical Provides Strategic Outlook
Dec. 01, 2020
Todos Medical Completes Installation of Lab Automation Equipment at Wisconsin Lab Client to Support COVID-19 PCR Testing
Nov. 24, 2020
Todos Medical Announces Positive In Vitro Data for Tollovid™ Confirming 3CL Protease Inhibition Mechanism of Action
Nov. 20, 2020
Todos Medical Announces Positive Initial Clinical Proof-of-Concept Data for a Rapid SARS-CoV-2 3CL Protease Detection Assay
Nov. 18, 2020
Todos Medical Announces Clinical Validation and National CLIA Certification for MOTO+PARA Mobile High Complexity Labs
Nov. 17, 2020
Todos Medical Announces $867,000 in Sales for October 2020
Nov. 12, 2020
Todos Medical Trademarks Tollovid for Dietary Supplement NLC-001 and Enters Into Private Label & Distribution Agreement With The Alchemists Kitchen
Oct. 29, 2020
Todos Medical Announces Instrument Validation Complete at MOTO+PARA Mobile Lab
Oct. 26, 2020
Todos Medical Announces Distribution Agreement with Adial Pharmaceuticals to Market the FDA, EUA Authorized, Assure/FaStep Point-of-Care Covid-19 Antibody Tests
Oct. 22, 2020
Todos Medical Receives Notices of Allowance From the European Patent Office Covering Use of TBIA Cancer Platform to Detect Benign Colon Cancer
Oct. 20, 2020
Todos Medical Reports $2.0 Million in Revenue for the Third Quarter of 2020
Oct. 13, 2020
Todos Medical Enters into Exclusive COVID-19 Testing Supply Agreement with MOTO+PARA’s National Mobile CLIA Lab Partner Integrated Health
Oct. 07, 2020
Todos Medical Enters into Exclusive Branding and Distribution Agreement with Melbourne Biotech for 96 and 384 Well RT-PCR Machines in the United States
Sep. 30, 2020
Todos Medical Enters Into COVID-19 PCR Testing Implementation and Equipment Financing Partnership with AID Genomics
Sep. 25, 2020
Todos Medical Expands Existing Contract for COVID-19 PCR Testing Equipment & Supplies with Wisconsin-based Laboratory to $47.5 Million
Sep. 22, 2020
Todos Medical CEO Releases Letter to Shareholders
Sep. 18, 2020
3CL Protease Inhibitor NLC-001 Added to COVID-19-focused Joint Venture Between Todos Medical and NLC Pharma
Sep. 17, 2020
Todos Medical Expands Partnership with Care G.B. Plus for Proprietary TBIA Cancer Tests to Include Europe, Israel and Africa
Sep. 16, 2020
Todos Medical Announces Commercial Launch of Todos Branded COVID-19 qPCR Test Kits in the United States
Sep. 11, 2020
Todos Medical Announces August Sales of $1,190,000, Up 100% Compared with July
Sep. 03, 2020
Todos Medical Enters Into Partnership With Pangea for COVID-19 Testing and Contact Tracing
Sep. 02, 2020
Todos Medical Announces $23,760,000 Contract for COVID-19 PCR Testing Equipment & Supplies With Wisconsin-based Laboratory
Aug. 31, 2020
Todos Medical to Present at The LD 500 Virtual Conference
Aug. 31, 2020
Todos Medical Announces $4,500,000 Contract for COVID-19 PCR Testing Equipment & Supplies with New York-based Laboratory
Aug. 27, 2020
Todos Medical Appoints Marsha Fontanive as VP of Sales and Chris Gross as VP of Sales Operations
Aug. 25, 2020
Todos Medical Announces $1.2 Million Contract for COVID-19 PCR Testing Equipment & Supplies with Texas-based Laboratory
Aug. 24, 2020
Todos Medical Announces $6,000,000 Contract for COVID-19 PCR Testing Equipment & Supplies with New York-based Laboratory
Aug. 21, 2020
Todos Medical Announces Positive Proof-of-Concept Data for Novel 10-Minute Point-of-Care Saliva-based Test Detecting Active SARS-CoV-2 Infection
Aug. 17, 2020
Todos Medical Acquires Distribution Rights to SARS-CoV-2 Rapid Point-of-Care Antigen Test and Rapid Point-of-Care PCR Test
Aug. 14, 2020
Todos Medical Announces July Sales of COVID-19 Tests
Aug. 07, 2020
Todos Medical Announces Common Stock Purchase Agreement with Lincoln Park Capital Fund, LLC
Aug. 06, 2020
Todos Medical Appoints Dr. Jorge Leon as Consulting Chief Medical and Scientific Officer of Infectious Disease and Oncology
Aug. 04, 2020
Pathnova Laboratories (PATHNOVA) Enters into Partnership to Commercialize Todos Medicals COVID-19 and Breast Cancer Tests in Singapore
Aug. 03, 2020
Todos Medical Completes Acquisition of Breakthrough Diagnostics, Gains Full Rights to the Alzheimer’s Blood Diagnostic LymPro™ Test from Amarantus
Jul. 28, 2020
Todos Medical Announces SARS-nCoV-19 Testing Kit Contract with NJ-Based Best Supply Clinical Laboratory
Jul. 27, 2020
Todos Medical Expands Management Team and Advisory Board
Jul. 20, 2020
Todos Medical Announces ANVISA Authorization in Brazil for 3D Med qPCR Kits and ANDis Extraction S
Jul. 16, 2020
Todos Medical Releases Letter to Shareholders
Feb 07, 2020 9:15am EST
Todos Medical Enters into Exclusive Option Agreement to Acquire Provista Diagnostics and Announces Management Changes
Jan 09, 2020 8:00am EST
Todos To Present At Upcoming 12th Annual LD Micro Main Event
Dec 06, 2019 7:29am EST
Todos and Amarantus JV Announces Full Enrollment for Clinical Trial of LymPro Alzheimer’s Blood Test Relationship with Amyloid PET
Nov 14, 2019 11:02am EST
Todos Medical to Present at Dawson James Small Cap Growth Conference
Oct 24, 2019 9:25am EDT
Todos Medical and Orot+ Announce First Patient Enrolled in Pre-Commercial Launch Preparations of TM-B1 and TM-B2 Breast Cancer Blood Screening Tests in Europe
Sep 24, 2019 9:14am EDT
Todos Medical Signs Binding Term Sheet with HWH World for Network Marketing of Blood Tests for the Early Detection of Breast Cancer
Sep 13, 2019 7:30am EDT
Todos Medical Enters into MOU to Expand Existing Early Detection Breast Cancer Blood Test Distribution Partnership with Orot+ into Japan
Sep 03, 2019 1:29pm EDT
Todos Medical Appoints Dr. Jorge Leon as Medical Advisor
Aug 06, 2019 7:00am EDT
Todos Medical Announces Positive Alzheimer's Biomarker Clinical Data from LymPro vs. Amyloid PET Interim Analysis
Jul 15, 2019 7:00am EDT
Todos Medical CEO Presented Corporate Update And Roadmap at The LD Micro Conference
Jun 17, 2019 8:30am EDT
Todos Medical Announces Positive Clinical Trial Data for Breast Cancer Blood Test TM-B1 in Dense Breasts
Jun 03, 2019 8:00am EDT
Todos Medical Exercises Option to Acquire Remaining 80.01% of Breakthrough Diagnostics from Amarantus After Review of Alzheimer's Blood Test Data
May 28, 2019 8:57am EDT
Todos Medical Receives Approval from Israeli Ministry of Health (AMAR) to Market and Sell its Breast Cancer Screens in Israel
May 23, 2019 8:00am EDT
Todos Medical Enters Exclusive Distribution Agreement with Care G.B. Plus, Ltd. for its Breast Cancer Screening Tests in Israel
May 21, 2019 8:00am EDT
Todos Medical Announces Voting Results from 2019 Annual Shareholder Meeting
May 03, 2019 8:52am EDT
Todos Medical Receives Notice of Allowance from the USPTO Covering the Early Diagnosis of Lung Cancer Using the Todos Biochemical Infrared Analysis (TBIA)
May 01, 2019 8:00am EDT
Todos Medical Enters Into Definitive Agreement With Orot+ for Exclusive Distribution Rights of its Breast Cancer Screening Tests in 2 European Countries
Apr 15, 2019 8:00am EDT
Todos and Amarantus Announce Completion of LymPro PET 1 Study by Leipzig University for Alzheimer’s Blood Diagnostic LymPro Test 2.0
Apr 08, 2019 7:30am EDT
Todos Medical to Present at Two Upcoming Investor Conferences
Mar 28, 2019 8:00am EDT
Todos Medical Appoints Dr. Colin Bier to Its Board of Directors
Mar 27, 2019 8:00am EDT
Todos Medical Raises $1,350,500 In Funding and Finalizes Joint Venture Agreement with Amarantus Bioscience
Feb 28, 2019 9:30am EST
Todos Medical Presents Encouraging Scientific Abstract at the San Antonio Breast Cancer Symposium (SABCS)
Dec 06, 2018 4:00pm EST
Todos Medical Enters into Joint Venture Agreement with Amarantus to develop Alzheimer’s Blood Diagnostic LymPro Test 2.0
Dec 03, 2018 8:30am EST
Todos Medical to Present Scientific Abstract at the Upcoming San Antonio Breast Cancer Symposium (SABCS)
Nov 29, 2018 8:30am EST
Todos Medical, Ltd. Announces Additional Patent Issuance Covering the Use of IR Spectrum of Blood Plasma For Indicating the Presence of Breast Cancer
Oct 17, 2018 8:30am EDT
Todos Medical, Ltd. Signs Non-Binding Memorandum of Understanding with Orot+ for Distribution Rights of its Breast Cancer Screening Tests in Romania and Austria
Sep 13, 2018 8:30am EDT
Todos Medical, Ltd. Appoints Herman Weiss, MD MBA as New Chief Executive Officer
Jul 31, 2018 4:03pm EDT
Todos Medical reports on results of clinical trials for its blood test for breast cancer screening (TM - B1) conducted at Kaplan Hospital in Rehovot, Israel
Mar 22, 2018 8:00am EDT
Todos Medical initiates clinical trial of its blood test for breast cancer in Kaplan Hospital, Rehovot, Israel for subjects undergoing breast cancer screening
Mar 05, 2018 8:00am EST
U.S. Patent and Trademark Office has granted to Todos Medical two additional patents
Feb 12, 2018 8:00am EST
Mr. David Ben Naim, CPA, MBA Joins Todos Medical as Chief Financial Officer
Feb 06, 2018 8:00am EST
Todos Medical Appoints Dr. Meir Silver as Vice President of Clinical Research and Regulatory Affairs
Aug 29, 2017 8:30am EDT
buy hey, here's to all your TOMDF stock buys Redsee:
SMH - nuff said
MOO pathetic
haven't any of the TOMDF Back Office Promo Boyzzz heard...?
below quote direct from Gerald Commissiong disgraced TOMDF CEO:
gotts to love those CYA Disclaimers
you know Redsee - the ones that warn about the legal perils of false representation - eh...?
SMH - can't make this Fairy Dust up folks...!
MOO dookie
Taobao - what hooie...!
China has a million gromwell root sellers and distributors in-country
https://www.made-in-china.com/products-search/hot-china-products/Gromwell_Root.html
who needs some unproven overpriced import ...
when Chinese folks can get authentic gromwell root from their very own trustworthy people
sounds Slim Shady to me...
MOO dorkus maximus
the only fake Dr around here is the one who spends all day tweeting on X
Gerald Commissiong twice failed Stanford U "Financial Engineer" CEO hack taking on Elon Musk...?
oh really - big man on campus - eh Redskee...?
Elon Musk would eat Geralds lunch, then wipe the floors with him for desert
but that ain't as bad as the TOMDF Back Office Promo Boyzzzz who pump this diluted sham daily
by insinuation of making share purchases while simultaneously ....
trying to entice the novice unsuspecting and noob investor to buy into this sham
buyer be ware - TOMDF has 3-Bil. OS share count and is financed with toxic death spiral dilutive conversions
also be ware of pumpers Redspeed, JoeForkeyBolo, TheWordman and a few others that will try to entice you to buy this shite:
printing $0.0003 says it all folks - just LOOKIE here:
SMH - nuff said...
MOO dunce
MM 3:15 Dr. Jen Curtin
Paxlovid was top item ordered...
fortunately its FDA approved, Rx distributed and covered by insurance
Metformin next item mentioned and highly touted...
fortunately its FDA approved, Rx distributed and covered by insurance
"can't speak to efficacy of Tollovid" - as stated by Doc Stuart Malcolm
funny - you don't need "real" Dr's to Rx tollivid - cause you don't need one - its a common cold OTC remedy & store shelf "supplement"
AOL is where it all started - some peeps just like a good old fashion browser that works
but hey, how's that Anti-Covid pill doing from your twice failed Stanford University "Financial Engineering" wannbe CEO hack:
FYI here's what your Gerry lust Stanford University "Financial Engineer" did to his loyal TOMDF shareholders
printing $0.0003 with over 3-Bil. OS printed & outstanding
guess anything bought at $0.0004 and above is under water - YIKES Redskee YIKES
Gerald eviscerated TOMDF shareholder's $$$ right out of their hands
not once but twice - with AMBS dead on arrival AND stuck in the trip's:
SMH can't make this shite up...!
oh that look on Stuart Varney's face says it all folks...
MOO hooie